Physician-guided care in Florida and ColoradoFL (954) 953-3662  |  CO (720) 902-8247
Home / Guides / PCOS, Insulin Resistance and Weight: What the Evidence Says

PCOS, Insulin Resistance and Weight: What the Evidence Says

PCOS affects 10 to 13 percent of women worldwide. See what the 2023 guideline and trials say about insulin resistance, lifestyle, metformin and GLP-1 drugs.

Before and after photo of a Healthy Weight Loss 4 U patient; individual results vary
Real Healthy Weight Loss 4 U patient photo. Individual results vary and are not guaranteed.

By the Healthy Weight Loss 4 U Clinical Content Team · Published October 19, 2026 · Updated October 19, 2026 · 9 min read

In short

PCOS affects an estimated 10 to 13 percent of women worldwide, and the 2023 international guideline recommends lifestyle intervention for everyone with the condition, with benefits even when weight does not change [1]. Metformin and GLP-1 receptor agonists have been studied for weight in PCOS, but metformin is not FDA approved to treat PCOS [5] and none of the GLP-1 labels we reviewed lists PCOS as an indication [13][14][15].

Key takeaways

  • The 2023 international guideline puts PCOS prevalence at 10 to 13 percent globally using the Rotterdam criteria, which require two of three features in adults [1].
  • In a meta-analysis of 35 studies, women with PCOS had 4.00 times the odds of type 2 diabetes even when compared with women of similar BMI (odds ratio 4.00, 95% CI 1.97 to 8.10) [7].
  • A Cochrane review of 6 randomized trials (164 women) found lifestyle programs lowered body weight by 3.47 kg on average versus minimal treatment, along with lower testosterone and fasting insulin [8].
  • A meta-analysis of 12 randomized trials (608 women) found metformin alone produced BMI changes similar to lifestyle change at 6 months [9].
  • The wording of the current Wegovy, Zepbound and Saxenda labels covers weight reduction in obesity or overweight, not PCOS, and a 2024 review found published data on anti-obesity drugs in PCOS to be very limited [10][13][14][15].

What is PCOS and how common is it?

Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women of reproductive age, and the 2023 international evidence-based guideline reports a global prevalence of 10 to 13 percent when the Rotterdam criteria are used [1]. It is a syndrome, which means no single finding is enough to define it [6].

The 2003 Rotterdam consensus described the clinical picture as menstrual irregularity, signs of androgen excess (male-pattern hormones such as testosterone) and obesity, with insulin resistance and raised luteinizing hormone also common. It also linked PCOS to a higher risk of type 2 diabetes and cardiovascular events [6]. The National Institute of Child Health and Human Development (NICHD) adds that the exact cause is unknown and that genetic and environmental factors both contribute [3].

Weight is part of the picture but not the whole of it. NICHD states that about 4 out of 5 women with PCOS also have obesity [2], yet PCOS also occurs at lower body weights, and the guideline includes recommendations for adults with a BMI under 25 kg/m2 [1]. Symptoms listed by NICHD include irregular periods, infertility, excess hair growth, persistent acne and dark, thickened skin patches [2].

How is PCOS diagnosed?

In adults, PCOS is diagnosed when two of three features are present: signs or lab evidence of high androgens, irregular or absent ovulation, and polycystic-appearing ovaries [1][4]. A clinician must also rule out other causes of high androgens before making the diagnosis [1].

The three Rotterdam features. Adults need two of the three [1][4].
FeatureWhat a clinician looks atNotes from the 2023 guideline
HyperandrogenismExcess hair growth (hirsutism) or blood androgen levelsHirsutism alone should be considered predictive of biochemical hyperandrogenism and PCOS in adults [1]
Ovulatory dysfunctionCycle length and number of cycles per yearFrom 3 years after first period to perimenopause, irregular means cycles shorter than 21 or longer than 35 days, or fewer than 8 cycles a year [1]
Polycystic ovarian morphologyUltrasound, or in adults an anti-Mullerian hormone (AMH) blood testAMH can be used in adults but should not be the single test for diagnosis, and both tests should not be done, to limit overdiagnosis [1]

The criteria differ for teenagers. The guideline says adolescents need both hyperandrogenism and ovulatory dysfunction, and that ultrasound and AMH are not recommended for them [1]. NICHD notes that some adolescents with characteristic features may be considered at risk and reevaluated later [4].

The 2004 Rotterdam consensus article in Fertility and Sterility established that no single criterion, such as hyperandrogenism or polycystic ovary appearance, is sufficient for a clinical diagnosis [6].

This is why a diagnosis is more than a single lab value. A clinician reviews the pattern of cycles, looks for signs of androgen excess, and considers other explanations for the findings, which the guideline says can include ovarian and adrenal neoplastic growths [1]. The 2013 Endocrine Society guideline also described diagnosis as problematic in adolescents and in menopausal women [12].

How do insulin resistance and high androgens relate to weight?

Insulin resistance is common in PCOS and is linked to higher androgen levels, but the evidence describes association and mechanism, not a single cause. NICHD states that more than half of women with PCOS have insulin resistance, and that extra insulin prompts the body to make more androgens, which contribute to symptoms [2][3]. NICHD also notes that it is difficult to disrupt this cycle, which is one reason PCOS can be challenging to treat [3].

The most useful data on whether this is only a weight effect come from a 2010 meta-analysis of 35 studies. Women with PCOS had higher odds of impaired glucose tolerance, type 2 diabetes and metabolic syndrome, and the odds stayed elevated in studies that matched women by BMI [7].

Odds ratios for women with PCOS versus women without PCOS, in studies matched for BMI

Source: [7] Moran et al., Human Reproduction Update 2010 (BMI-matched subgroup analyses). Confidence intervals are wide for type 2 diabetes (1.97 to 8.10).

Weight also seems to be harder to manage in PCOS for reasons beyond behavior. The guideline states that many women with PCOS have underlying mechanisms that drive greater weight gain over time and a higher BMI, and that there is no consistent evidence of lifestyle differences related to weight between women with and without PCOS [1]. NICHD reports that 25 to 45 percent of women with PCOS have metabolic syndrome, and more than half develop type 2 diabetes or prediabetes before their early 40s [2].

Insulin resistance itself is hard to measure in the clinic. The guideline says routine insulin assays are inaccurate and of limited clinical relevance, so measuring insulin resistance is not recommended in routine care, even though insulin resistance is considered a pathophysiological factor in PCOS [1].

What do trials show for lifestyle change in PCOS?

Lifestyle programs improve weight, androgen measures and fasting insulin in small randomized trials, and the 2023 guideline recommends lifestyle intervention for all women with PCOS [1]. The evidence base is modest in size.

A Cochrane review pooled 6 randomized trials with 164 participants that compared exercise, or diet plus exercise and behavioral programs, with minimal or no treatment. Lifestyle intervention lowered body weight by 3.47 kg, waist circumference by 1.95 cm, total testosterone by 0.27 nmol/L, hirsutism score by 1.19 points and fasting insulin by 2.02 microunits/mL. It found no clear effect on BMI, glucose or cholesterol, and no usable data on fertility, quality of life or acne. Only 4 of the 6 trials had adequate sequence generation and blinding of assessors [8].

The guideline adds several points. A healthy lifestyle with structured, ongoing support appears equally effective in PCOS as in the general population, there are benefits even without weight loss, and no one diet composition has been shown to be better than another [1]. For activity, it suggests at least 150 to 300 minutes of moderate-intensity activity a week to prevent weight gain and at least 250 minutes a week for greater benefit including modest weight loss, with adolescents aiming for at least 60 minutes a day [1].

Not every source treats weight loss as central to PCOS. Readers should also note the limits of the Cochrane review: 164 participants in total, and a last search date of 2010, so newer trials are not included [8]. The 2013 Endocrine Society guideline, now marked retired, said lifestyle intervention is beneficial in overweight or obese patients for other health benefits, while the role of weight loss in improving PCOS status itself was uncertain [12].

Does metformin help with weight in PCOS?

Metformin can be considered in PCOS, but it is not FDA approved to treat PCOS, and its weight effect appears similar to lifestyle change rather than larger. NICHD states that insulin-sensitizing medications such as metformin are not FDA approved to treat PCOS [5], and a DailyMed metformin extended-release label lists its indication as improving glycemic control in adults with type 2 diabetes [16].

The guideline says metformin alone should be considered in adults with PCOS and a BMI of 25 kg/m2 or higher, and may be considered below that BMI while acknowledging limited evidence. It also tells clinicians to inform women that metformin and active lifestyle intervention have similar efficacy [1].

Metformin and lifestyle: pooled randomized-trial results
StudyDesignFinding
Naderpoor et al., 2015 [9]12 randomized trials, 608 women with PCOS, 6-month outcomesLifestyle plus metformin vs lifestyle: BMI lower by 0.73 kg/m2, subcutaneous fat lower by 92.49 cm2, 1.06 more menstrual cycles
Naderpoor et al., 2015 [9]Same review, metformin alone vs lifestyleWeight and BMI similar at 6 months; testosterone lower with metformin
Endocrine Society, 2013 [12]Retired guidelineMetformin beneficial for metabolic and glycemic abnormalities; limited or no benefit for hirsutism, acne or infertility

The authors of the 2015 review noted small samples, short duration and risk of bias, and called for larger and longer studies [9].

Where do GLP-1 medications fit in PCOS?

No GLP-1 drug is FDA labeled for PCOS. The current prescribing information for Wegovy (revised 6/2026), Zepbound (revised 8/2026) and Saxenda (revised 6/2026) describes use alongside diet and activity to reduce excess body weight in adults with obesity, or overweight with a weight-related condition, and none of the indication sections lists PCOS [13][14][15]. Zepbound is also indicated for moderate to severe obstructive sleep apnea in adults with obesity [14].

The guideline takes a cautious position. It says anti-obesity medications, including liraglutide, semaglutide and orlistat, could be considered in addition to active lifestyle intervention. It also says effective contraception is needed when pregnancy is possible because pregnancy safety data are lacking, and that people should hear about the high risk of weight regain after stopping and the lack of long-term safety data. For reproductive outcomes, it recommends using anti-obesity agents only in research settings [1].

The trial evidence is thin. A 2024 systematic review done to inform the guideline found 11 trials (545 participants in intervention arms and 451 in control arms). Liraglutide, semaglutide and orlistat appeared better than placebo for weight measures, but only two comparisons could be pooled, and the authors concluded that published data on anti-obesity agents in PCOS are very limited [10]. In the one head-to-head pooled comparison of exenatide versus metformin (2 trials), there were no differences in weight, androgen or metabolic outcomes except that fasting glucose was lower with metformin (mean difference 0.10 mmol/L), and adding orlistat to a combined oral contraceptive did not improve metabolic outcomes [10].

A 2021 meta-analysis of randomized trials in overweight or obese women with PCOS found that GLP-1 receptor agonists, alone or with metformin, lowered weight more than metformin alone (weighted mean difference -2.61, 95% CI -3.51 to -1.72, 318 participants) and waist circumference more (-3.46, 276 participants). Heterogeneity across the weight and BMI results was high (I-squared 77.5 percent and 84.9 percent), and the authors called for larger trials [11]. Whether a GLP-1 prescription is appropriate for a particular person is a decision for a licensed clinician after an evaluation.

What else does the guideline say to check besides weight?

The guideline recommends checking blood sugar status and mood, not only weight. Glycaemic status should be assessed at diagnosis in all adults and adolescents with PCOS, a 75-gram oral glucose tolerance test is the recommended most accurate test, and glycaemic status should be reassessed every one to three years depending on individual risk factors [1].

It also recommends screening for depression in all adults and adolescents with PCOS [1], and notes that terms such as overweight and obese can be stigmatizing, suggesting language such as higher weight [1]. NICHD says providers should screen women with PCOS for cardiovascular disease on a regular basis [2]. Oral contraceptives are described by NICHD as the primary long-term treatment option for people with PCOS who do not want pregnancy [5].

What this means in practice

  • A PCOS diagnosis uses the Rotterdam features, two of three in adults, after other causes of high androgens are ruled out [1][4].
  • Fasting insulin tests are not recommended for routine care because the assays are inaccurate, so a normal insulin level does not rule out PCOS [1].
  • Lifestyle intervention is recommended for everyone with PCOS, and the guideline notes benefits even without weight loss, with no single diet shown to be best [1].
  • Metformin is not FDA approved for PCOS, and its pooled weight effect in trials was similar to lifestyle change [5][9].
  • No GLP-1 medication is FDA labeled for PCOS, and published trials in PCOS are small and limited, so any use is a clinician decision made after an evaluation [10][13][14][15].
  • Ask about blood sugar testing and depression screening, which the guideline recommends for people with PCOS [1].
  • If pregnancy is possible, tell the clinician before any weight medication, since the guideline says pregnancy safety data are lacking [1].

When to talk to a clinician

Consider an evaluation if you have cycles shorter than 21 days or longer than 35 days, fewer than 8 cycles a year, excess facial or body hair, persistent acne, or trouble getting pregnant, since these are the features used to diagnose PCOS [1][2]. Weight gain that is hard to reverse, especially around the waist, is also listed by NICHD among PCOS symptoms [2].

At Healthy Weight Loss 4 U, every program begins with a clinician evaluation, and that evaluation is the place to raise PCOS, cycle changes and any prior diagnosis or medications. Whether any treatment is appropriate for you is decided by a licensed clinician after that evaluation, and we cannot promise any result.

Frequently asked questions

How common is PCOS?
The 2023 international guideline reports a global prevalence of 10 to 13 percent when the Rotterdam criteria are used [1]. NICHD says the exact cause is unknown and that genetic and environmental factors both appear to contribute [3]. Many people are diagnosed only after trouble getting pregnant or after developing irregular periods [2].
Does PCOS cause weight gain?
The guideline says many women with PCOS have underlying mechanisms that drive greater weight gain over time and a higher BMI, but it also found no consistent evidence of lifestyle differences related to weight between women with and without PCOS [1]. NICHD reports that about 4 out of 5 women with PCOS also have obesity [2]. These are associations, and PCOS also occurs at lower weights [1].
Do I need an insulin test to be diagnosed with PCOS?
No. The guideline says routinely available insulin assays are inaccurate and not recommended in routine care, even though insulin resistance is considered a factor in PCOS [1]. Diagnosis in adults rests on two of three features: high androgens or signs of them, irregular ovulation, and polycystic-appearing ovaries on ultrasound or, in adults, an AMH blood test used with other findings [1][4].
Is metformin approved for PCOS?
No. NICHD states that insulin-sensitizing medications such as metformin are not FDA approved to treat PCOS [5]. A DailyMed metformin extended-release label lists type 2 diabetes as its indication [16]. The 2023 guideline says metformin can be considered in adults with PCOS and says it has similar efficacy to active lifestyle intervention [1].
Is any GLP-1 drug FDA approved for PCOS?
No. The Wegovy, Zepbound and Saxenda labels describe weight reduction in obesity or overweight with a weight-related condition, and none of the indication sections mentions PCOS [13][14][15]. The 2023 guideline says liraglutide, semaglutide and orlistat could be considered alongside lifestyle intervention, with pregnancy safety data lacking [1].
What does the guideline say about exercise for PCOS?
It suggests at least 150 to 300 minutes of moderate-intensity activity per week to prevent weight gain, and at least 250 minutes per week for greater benefit including modest weight loss. Adolescents should aim for at least 60 minutes of moderate to vigorous activity daily [1]. It also notes benefits even in the absence of weight loss [1].
Can PCOS be diagnosed in teenagers?
Yes, with stricter criteria. The guideline says adolescents need both hyperandrogenism and ovulatory dysfunction, and that ultrasound and AMH testing are not recommended for them [1]. NICHD notes that some adolescents with characteristic features may be considered at risk and reevaluated later [4].
Does losing weight cure PCOS?
There is no cure in the sources reviewed. In a Cochrane review of 6 small trials, lifestyle programs lowered weight, testosterone and fasting insulin [8], and the guideline recommends lifestyle intervention for all women with PCOS [1]. The 2013 Endocrine Society guideline said the role of weight loss in improving PCOS itself was uncertain [12].

Sources

  1. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction (Teede HJ, Tay CT, Laven J, et al.), 2023. doi.org/10.1093/humrep/dead156
  2. What are the symptoms of PCOS? (and related conditions). NICHD, National Institutes of Health, n.d. (accessed Oct 2026). www.nichd.nih.gov/health/topics/pcos/conditioninfo/symptoms
  3. What causes PCOS?. NICHD, National Institutes of Health, n.d. (accessed Oct 2026). www.nichd.nih.gov/health/topics/pcos/conditioninfo/causes
  4. How do health care providers diagnose PCOS?. NICHD, National Institutes of Health, n.d. (accessed Oct 2026). www.nichd.nih.gov/health/topics/pcos/conditioninfo/diagnose
  5. What are the treatments for PCOS?. NICHD, National Institutes of Health, n.d. (accessed Oct 2026). www.nichd.nih.gov/health/topics/pcos/conditioninfo/treatments
  6. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility, 81(1):19-25, 2004. doi.org/10.1016/j.fertnstert.2003.10.004
  7. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update (Moran LJ, Misso ML, Wild RA, Norman RJ), 2010. academic.oup.com/humupd/article/16/4/347/802669
  8. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews (Moran LJ, Hutchison SK, Norman RJ, Teede HJ), 2011. www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007506.pub2/abstract
  9. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Human Reproduction Update (Naderpoor N, et al.), 2015. academic.oup.com/humupd/article-abstract/21/5/560/565592
  10. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews (Goldberg A, et al.), 2024. doi.org/10.1111/obr.13704
  11. The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight/Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. International Journal of Endocrinology (Lyu X, et al.), 2021. doi.org/10.1155/2021/6616693
  12. Diagnosis and Treatment of Polycystic Ovary Syndrome (retired guideline). Endocrine Society, 2013. www.endocrine.org/clinical-practice-guidelines/polycystic-ovary-syndrome
  13. WEGOVY (semaglutide) prescribing information, Indications and Usage (revised 6/2026). DailyMed, National Library of Medicine, 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  14. ZEPBOUND (tirzepatide) prescribing information, Indications and Usage (revised 8/2026). DailyMed, National Library of Medicine, 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  15. SAXENDA (liraglutide) prescribing information, Indications and Usage (revised 6/2026). DailyMed, National Library of Medicine, 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  16. Metformin hydrochloride extended-release tablets prescribing information, Indications and Usage (revised 5/2021). DailyMed, National Library of Medicine, 2021. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1452fbb1-e591-4a51-9f83-8a8a6a780b52
General information, not medical advice. Results vary and treatment depends on evaluation by a licensed clinician. This article was prepared by the Healthy Weight Loss 4 U Clinical Content Team from the published sources listed above. Nothing here is a recommendation for a specific person, and no treatment is started without an evaluation by a licensed clinician.

Keep reading

Health Benefits of 5 to 15 Percent Weight Loss

Read →

How GLP-1 Medications Work for Weight Loss

Read →

Who Qualifies for Medical Weight Loss? BMI and FDA Criteria

Read →

Sleep and Weight: How Short Sleep and Stress Affect Appetite

Read →

Prediabetes, Type 2 Diabetes and Weight Loss: What Trials Show

Read →

Questions about your own situation? A clinician can review your history and goals. Related: Personalized Weight Loss Counseling.

Book in Lighthouse Point, FL Book in Highlands Ranch, CO